EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY 4.0

Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial

Xiangjin Gao, Ruiqi Cai, Jinrong Lu, Zhen Duan, Quanruo Xu, Xiuqi Zhang, Fanlingzi Shen, Rui Zhang, Bin Li, Ruiping Wang

Frontiers in Medicine · 21.05.2026 · 13

DOI: 10.3389/fmed.2026.1845534 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift Frontiers in Medicine, online erschienen am 21.05.2026. Verfasst von Xiangjin Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Research Center, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission Traditional Chinese Medicine Standard Research Project, China Fund for Medical Equipment, Clinical Research Program of Shanghai Municipal Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atopic dermatitis (AD) is a prevalent chronic and recurrent inflammatory skin disease. Guidelines for the treatment and care of AD suggest that appropriate bathing can facilitate the repair of skin lesions. MuShengshu is a weakly acidic bath solution that contains traditional Chinese medicine ingredients. Previous studies indicate its potential to alleviate pruritus and promote the healing of skin lesions in patients with dermatosis. However, high-quality evidence is still limited.

Objectives

This randomized, double-blind, placebo-controlled clinical trial aims to assess the efficacy and safety of MuShengshu (MSS) combined with foundational therapies in patients with mild-to-moderate AD.

Methods

A total of 66 patients with mild-to-moderate AD will be enrolled at the Shanghai Skin Disease Hospital from August 2025 to June 2026. Patients will be randomly assigned in a 2:1 ratio to either the treatment group (MSS combined with foundational therapies, n = 44) or the control group (MSS placebo combined with foundational therapies, n = 22). Patients will receive MSS or MSS placebo once daily, for 4 months. Meanwhile, the foundational therapies include desonide cream for mild AD and triamcinolone acetonide cream for moderate AD, both of which will be applied twice daily for 2 weeks. Additionally, all patients will receive urea ointment twice daily for 4 weeks. The primary outcome indicator is EASI 50 , defined as the proportion of patients achieving ≥50% improvement in the Eczema Area and Severity Index (EASI) score at week 4 from baseline. The secondary outcome indicators include the EASI, Visual Analogue Scale (VAS), Investigator’s Global Assessment (IGA), and Dermatology Life Quality Index (DLQI), which will be assessed at baseline (week 0), weeks 1, 2, 4, and 16. In this study, statistical analyses will be conducted using SAS 9.4 software, with statistical significance being defined as a two-tailed α level of 0.05.

Results

In this study, ethical approval was granted in March 2025, with registration completed in the International Traditional Medicine Clinical Trial Registry in June 2025. Recruitment of participants began in August 2025 and is anticipated to completed by June 2026. Data analysis is set to start in August 2026, with preliminary trial results expected to be submitted for peer-reviewed publication by December 2026.

Conclusion

Findings in this study are expected to provide evidence for the incorporation of traditional Chinese herbal bath solutions into the comprehensive management of AD. Clinical trial registration https://www.chictr.org.cn/ , Identifier ITMCTR2025001206.

Schlagwörter

Stichwörter der Autor:innen

MuShengshuatopic dermatitisclinical trial protocolrandomized controlled trialtraditional Chinese herbal bath solutions

Autor:innen und Institutionen

  • Clinical Research Center, Shanghai Skin Disease Hospital, Tongji University, Shanghai, China.
  • School of Public Health, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
  • School of Medicine, Tongji University, Shanghai, China.

Förderung

  • Shanghai Municipal Health Commission Traditional Chinese Medicine Standard Research Project
  • China Fund for Medical Equipment
  • Clinical Research Program of Shanghai Municipal Health Commission
  • Clinical Research Plan of SHDC

Zitieren

APA

Gao, X., Cai, R., Lu, J., Duan, Z., Xu, Q., Zhang, X., Shen, F., Zhang, R., Li, B., & Wang, R. (2026). Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1845534

Vancouver

Gao X, Cai R, Lu J, Duan Z, Xu Q, Zhang X, et al. Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1845534

BibTeX
@article{Gao2026,
  author = {Gao, Xiangjin and Cai, Ruiqi and Lu, Jinrong and Duan, Zhen and Xu, Quanruo and Zhang, Xiuqi and Shen, Fanlingzi and Zhang, Rui and Li, Bin and Wang, Ruiping},
  title = {Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1845534}
}
Kostenlos starten →